BioNidum-based Liver Therapeutic
Liver Failure (Acute-on-chronic)
Key Facts
About Dimension Bio
Dimension Bio is a private, preclinical-stage biotech founded in 2021 and headquartered in Cambridge, USA, with a significant operational presence in Chicago. The company is developing a novel class of regenerative 'tissue therapeutics' using its proprietary BioNidum™ platform, which combines cells with a 3D-printed biomaterial matrix to enhance cell survival, integration, and function. With a lead program in acute-on-chronic liver failure and a platform validated through partnerships and a prior FDA-cleared bone graft product, Dimension Bio is positioned at the intersection of advanced biomaterials, cell therapy, and digital manufacturing. The company has raised a $12M Series A and is backed by a strong team and advisory boards with deep expertise in biomaterials and hepatology.
View full company profile